Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease

Neurotoxicity Research

Volumn 17, Issue 2, 2010, Pages 114-129

  Prediger, Rui D S ^a   Aguiar Jr , Aderbal S ^a   Rojas Mayorquin, Argelia Esperanza ^b,c,d   Figueiredo, Claudia P ^a   Matheus, Filipe C ^a   Ginestet, Laure ^b,c,d   Chevarin, Caroline ^c   Del Bel, Elaine ^e   Mongeau, Raymond ^c   Hamon, Michel ^c   Lanfumey, Laurence ^c   Raisman Vozari, Rita ^b,c,d  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d CNRS   (France)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

C57BL 6 mice; Intranasal; Learning and memory; MPTP; Olfactory system; Parkinson's disease; Water maze

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CASPASE 3; DOPAMINE; TYROSINE 3 MONOOXYGENASE; BIOGENIC AMINE; NEUROTOXIN;

AMNESIA; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN REGION; C57BL 6 MOUSE; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE DURATION; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG ADMINISTRATION ROUTE; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL MODEL; FUNCTIONAL MORPHOLOGY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MOUSE; NEUROCHEMISTRY; NISSL STAINING; NONHUMAN; OLFACTORY BULB; OLFACTORY DISCRIMINATION; PARKINSON DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; SMELLING DISORDER; SUBSTANTIA NIGRA; ANALYSIS OF VARIANCE; ANIMAL; AVOIDANCE BEHAVIOR; BRAIN LEVEL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INHIBITION (PSYCHOLOGY); INTOXICATION; INTRANASAL DRUG ADMINISTRATION; MAZE TEST; METABOLISM; METHODOLOGY; MOTOR ACTIVITY; RECOGNITION; SOCIAL BEHAVIOR;

MUS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADMINISTRATION, INTRANASAL; ANALYSIS OF VARIANCE; ANIMALS; AVOIDANCE LEARNING; BIOGENIC MONOAMINES; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; INHIBITION (PSYCHOLOGY); MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MPTP POISONING; NEUROCHEMISTRY; NEUROTOXINS; OLFACTION DISORDERS; PARKINSON DISEASE, SECONDARY; RECOGNITION (PSYCHOLOGY); SOCIAL BEHAVIOR; TYROSINE 3-MONOOXYGENASE;

EID: 77449132053     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12640-009-9087-0     Document Type: Article

References (71)

1. Albanese A, Bentivoglio M (1982) The organization of dopaminergic and nondopaminergic mesencephalocortical neurons in the rat. Brain Res 238:421-425
2. Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9:357-381
3. Bezard E, Gross CE, Fournier MC, Dovero S, Bloch B, Jaber M (1999) Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp Neurol 155:268-273
4. Bondi MW, Kaszniak AW (1991) Implicit and explicit memory in Alzheimer's disease and Parkinson's disease. J Clin Exp Neuropsychol 13:339-358
5. Bosboom JL, Stoffers D, Wolters ECh (2004) Cognitive dysfunction and dementia in Parkinson's disease. J Neural Transm 111: 1303-1315
6. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318:121-134
7. Bruck A, Aalto S, Nurmi E, Bergman J, Rinne JO (2005) Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiol Aging 26:891-898
8. Chiueh C, Markey SP, Burns RS, Johannessen JN, Pert A, Kopin IJ (1984) Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. Eur J Pharmacol 100:189-194
9. Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV (1992) Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. Brain 115:1701-1725
10. Coopersmith R, Weihmuller FB, Kirstein CL, Marshall JF, Leon M (1991) Extracellular dopamine increase in neonatal olfactory bulb during odor preference training. Brain Res 564:149-153
11. Da Cunha C, Gevaerd MS, Vital MA, Miyoshi E, Andreatini R, Silveira R, Takahashi RN, Canteras NS (2001) Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behav Brain Res 124: 9-18
12. Dantzer R, Bluthe RM, Koob GF, Le Moal M (1987) Modulation of social memory in male rats by neurohypophyseal peptides. Psychopharmacology 91:363-368
13. Dluzen DE (1992) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) reduces norepinephrine concentrations in the olfactory bulbs of male mice. Brain Res 586:144-147
14. Dluzen DE, Kefalas G (1996) The effects of intranasal infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) upon catecholamine concentrations within olfactory bulbs and corpus striatum of male mice. Brain Res 741:215-219
15. Dluzen DE, Kreutzberg JD (1993) 1-Methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) disrupts social memory/recognition processes in the male mouse. Brain Res 609:98-102
16. Dluzen DE, Muraoka S, Landgraf R (1998) Olfactory bulb norepinephrine depletion abolishes vasopressin and oxytocin preservation of social recognition responses in rats. Neurosci Lett 254:161-164
17. Doty RL (2008) The olfactory vector hypothesis of neurodegenerative disease: is it viable? Ann Neurol 63:7-15
18. Doty RL, Risser JM (1989) Influence of the D2 dopamine receptor agonist quinpirole on the odor detection performance of rat before and after spiperone administration. Psychopharmacology 98:310-315
19. Doty RL, Deems D, Stellar S (1988a) Olfactory dysfunction in Parkinson's disease: a general deficit unrelated to neurologic signs, disease state, or disease duration. Neurology 38:1237-1244
20. Doty RL, Fergusson-Segall M, Lucki I, Kreider M (1988b) Effects of intrabulbar injections of 6-hydroxydopamine on ethyl acetate odor detection in castrate and non-castrate male rats. Brain Res 444:95-103
21. Doty RL, Bromley SM, Stern MB (1995) Olfactory testing as an aid in the diagnosis of Parkinson's disease: development of optimal discrimination criteria. Neurodegeneration 4:93-97
22. Douhou A, Debeir T, Murer MG, Do L, Dufour N, Blanchard V, Moussaoui S, Bohme GA, Agid Y, Raisman-Vozari R (2002) Effect of chronic treatment with riluzole on the nigrostriatal dopaminergic system in weaver mutant mice. Exp Neurol 176:247-253
23. Dubois B, Pillon B (1997) Cognitive deficits in Parkinson's disease. J Neurol 244:2-8
24. Duvoisin RC (1991) Parkinson's disease, 3rd edn. Raven Press, New York
25. Espejo EF (1997) Selective dopamine depletion within the medial prefrontal cortex induces anxiogenic-like effects in rats placed on the elevated plus maze. Brain Res 762:281-284
26. Fornai F, Schlüter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL, Pontarelli F, Battaglia G, Pellegrini A, Nicoletti F, Ruggieri S, Paparelli A, Südhof TC (2005) Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alphasynuclein. Proc Natl Acad Sci USA 102:3413-3418
27. Franco J, Prediger RD, Pandolfo P, Takahashi RN, Farina M, Dafre AL (2007) Antioxidant responses and lipid peroxidation following intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats: increased susceptibility of olfactory bulb. Life Sci 80:1906-1914
28. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. Academic Press, San Diego
29. Gall CM, Hendry SH, Seroogy KB, Jones EG, Haycock JW (1987) Evidence of coexistence of GABA and dopamine in neurons of the rat olfactory bulb. J Comp Neurol 266:307-318
30. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987-1041
31. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ (1998) The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50:1346-1350
32. Growdon JH, Kieburtz K, McDermott MP, Panisset M, Friedman JH (1998) Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group. Neurology 50:1327-1331
33. Halasz N, Shepherd GM (1983) Neurochemistry of the vertebrate olfactory bulb. Neuroscience 10:759
34. Hamon M, Fattaccini CM, Adrien J, Gallissot MC, Martin P, Gozlan H (1988) Alterations of central serotonin and dopamine turnover in rats treated with ipsapirone and other 5-hydroxytryptmaine 1A agonists with potential anxiolytic properties. J Pharmacol Exp Ther 246:745-752
35. Hirsch EC, Lejeune O, Colliot G, Corkidi G, Tajani M (1992) Computer methods in nuclei cartography. Methods Neurosci 10:62-79
36. Jenner P (2008) Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Ann Neurol Suppl 2:S16-S29
37. Kalaria RN, Mitchell MJ, Harik SI (1987) Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with bloodbrain barrier monoamine-oxidase activity. Proc Natl Acad Sci USA 84:3521-3525
38. Kaul S, Kanthasamy A, Kitazawa M, Anantharam V, Kanthasamy AG (2003) Caspase-3 dependent proteolyytic activation of protein kinase C delta mediates and regulates 1-methyl-4-phenylpyridinium (MPP?)-induced apoptotic cell death in dopaminergic cells: relevance to oxidative stress in dopaminergic degeneration. Eur J Neurosci 18:1387-1401
39. Kawano T, Margolis FL (1982) Transsynaptic regulation of olfactory bulb catecholamines in mice and rats. J Neurochem 39:342-348
40. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980
41. Lewis SJG, Dove A, Robbins TW, Barker RA, Owen AM (2003) Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 23:6351-6356
42. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92:180-185
43. Mattson MP (2000) Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 1:120-129
44. Mayer RA, Kindt MV, Heikkila RE (1986) Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport. J Neurochem 47:1073-1079
45. Mitsumoto Y, Mori A, Ohashi S, Nakai M, Moriizumi T (2005) Differential effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the olfactory bulb and the striatum in mice. Neurosci Res 51:111-115
46. Miyoshi E, Wietzikoski S, Camplessei M, Silveira R, Takahashi RN, Da Cunha C (2002) Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions. Brain Res Bull 58:41-47
47. Muller A, Reichmann H, Livermore A, Hummel T (2002) Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm 109:805-811
48. Passingham D, Sakai K (2004) The prefrontal cortex and working memory: physiology and brain imaging. Curr Opin Neurobiol 14:163-168
49. Petroske E, Meredith GE, Callen S, Totterdell S, Lau YS (2001) Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 106:589-601
50. Pillon B, Dubois B, Bonnet AM, Esteguy M, Guimaraes J, Vigouret JM, Lhermitte F, Agid Y (1989) Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15-objects test. Neurology 39:762-768
51. Poewe W, Berger W, Benke T, Schelosky L (1991) High-speed memory scanning in Parkinson's disease: adverse effects of levodopa. Ann Neurol 29:670-673
52. Prediger RD, Batista LC, Miyoshi E, Takahashi RN (2004) Facilitation of short-term social memory by ethanol in rats is mediated by dopaminergic receptors. Behav Brain Res 153:149-157
53. Prediger RD, Batista LC, Takahashi RN (2005a) Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors. Neurobiol Aging 26:957-964
54. Prediger RD, Da Cunha C, Takahashi RN (2005b) Antagonistic interaction between adenosine A2A and dopamine D2 receptors modulates the social recognition memory in reserpine-treated rats. Behav Pharmacol 16:209-218
55. Prediger RD, Batista LC, Medeiros R, Pandolfo P, Florio JC, Takahashi RN (2006) The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Exp Neurol 202:391-403
56. Prediger RD, Rial D, Medeiros R, Figueiredo CP, Doty RL, Takahashi RN (2009) Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) rat model of Parkinson's disease. Ann N Y Acad Sci. doi:10.1111/j. 1749-6632.2009.03885.x)
57. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R, Akran M (2001) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 76:1265-1274
58. Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 38: 277-301
59. Rojo AI, Montero C, Salazar M, Close RM, Fernandez-Ruiz J, Sanchez-Gonzalez MA, de Sagarra MR, Jackson-Lewis V, Cavada C, Cuadrado A (2006) Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. Eur J Neurosci 24:1874-1884
60. Sallaz M, Jourdan F (1992) Apomorphine disrupts odour-induced patterns of glomerular activation in the olfactory bulb. Neuroreport 3:833-836
61. Saporito MS, Brown EM, Miller MS, Carswell S (1999) CEP-1347/ KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J Pharmacol Exp Ther 288:421-427
62. Schintu N, Frau L, Ibba M, Garau A, Carboni E, Carta AR (2009) Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease. Neurotox Res 16:127-139
63. Schmidt N, Ferger B (2001) Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm 108:1263-1282
64. Schrag A (2004) Psychiatric aspects of Parkinson's disease: an update. J Neurol 251:795-804
65. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK (2000) MPTP susceptibility in the mouse: behavioral, nurochemical, and histological analysis of gender and strain differences. Behav Genet 30:171-182
66. Shipley MT, Halloran FJ, de la Torre J (1985) Surprisingly rich projection from locus coeruleus to the olfactory bulb in the rat. Brain Res 329:294-299
67. Stebbins GT, Gabrieli JD, Masciari F, Monti L, Goetz CG (1999) Delayed recognition memory in Parkinson's disease: a role for working memory? Neuropsychologia 37:503-510
68. Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, Takahashi RN (2008) Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 156:830-840
69. Weldon DA, Travis ML, Kennedy DA (1991) Posttraining D1 receptor blockade impairs odor conditioning in neonatal rats. Behav Neurosci 105:450-458
70. Xikota JC, Rial D, Ruthes D, Pereira R, Figueiredo CP, Prediger RD, Walz R (2008) Mild cognitive deficits associated to neocortical microgyria in mice with genetic deletion of cellular prion protein. Brain Res 1241:148-156
71. Zgaljardic DJ, Borod JC, Foldi NS, Mattis P (2003) A review of the cognitive and behavioral sequelae of Parkinson's disease: relationship to frontostriatal circuitry. Cogn Behav Neurol 16:193-210